...
首页> 外文期刊>Journal of Physiology and Biochemistry >Effect of recombinant erythropoietin on ischemia–reperfusion-induced apoptosis in rat liver
【24h】

Effect of recombinant erythropoietin on ischemia–reperfusion-induced apoptosis in rat liver

机译:重组促红细胞生成素对大鼠缺血再灌注后肝细胞凋亡的影响

获取原文
获取原文并翻译 | 示例

摘要

Ischemia–reperfusion (I/R) cannot be avoided in liver transplantation procedures, and apoptosis is a central mechanism of cell death after liver reperfusion. Protective effect of recombinant erythropoietin (rhEPO) on liver apoptosis has not been clearly investigated. This work investigated intraportal (IP) rhEPO-protective effect in a rat model of hepatic I/R-induced apoptosis and its appropriated time and dose of administration. Eight groups were included (n = 10/group): sham-operated, I/R (45 min ischemia and 2 h reperfusion), preconditioned rhEPO I/R (24 h or 30 min before ischemia), and postconditioned rhEPO I/R (before reperfusion) using two different rhEPO doses (1,000 and 5,000 IU/kg). When compared with the sham-operated group, the I/R group showed significant increase of serum levels of aspartate and alanine aminotransferases (AST, ALT), hepatic caspase-9 activity(894.99 ± 176.90 relative fluorescence units (RFU)/mg/min versus 458.48 ± 82.96 RFU/mg/min), and Fas ligand (FasL) expression, histopathological damages, and significant decrease in the antiapoptotic Bcl-xL/apoptotic Bax ratio(0.38 ± 0.21 versus 3.35 ± 0.77) rhEPO-improved ALT and AST but failed to reduce FasL expression in all groups compared with the I/R group. Thirty minutes and 24 h preconditioning with rhEPO (1,000 IU/kg) increased Bcl-xL/Bax ratio and reduced caspase-9 activity, and the same effect was observed when higher dose was given 24 h before ischemia. Preconditioning was more effective than postconditioning in improving caspase-9 activity, and no dose-dependent effect was observed. In conclusion, single IP rhEPO injection 30 min before ischemia has an advantage over rhEPO postconditioning in improving post-hepatic I/R-induced apoptosis with no additional time- and dose-dependent effects which may provide potentially useful guide in liver transplantation procedures.
机译:在肝移植过程中无法避免缺血再灌注(I / R),并且凋亡是肝脏再灌注后细胞死亡的主要机制。重组促红细胞生成素(rhEPO)对肝细胞凋亡的保护作用尚未明确研究。这项工作研究了肝I / R诱导的细胞凋亡大鼠模型中门内(IP)rhEPO的保护作用及其适当的给药时间和剂量。包括八组(n = 10 /组):假手术,I / R(缺血45分钟和再灌注2小时),预处理的rhEPO I / R(缺血前24小时或30分钟)和后置的r​​hEPO I / R (再灌注前)使用两种不同的rhEPO剂量(1,000和5,000 IU / kg)。与假手术组相比,I / R组的血清天冬氨酸和丙氨酸氨基转移酶(AST,ALT),肝胱天蛋白酶9活性(894.99±176.90相对荧光单位(RFU)/ mg / min)显着增加与458.48±82.96 RFU / mg / min相比)和Fas配体(FasL)的表达,组织病理学损害以及抗凋亡Bcl-xL /凋亡Bax比值的显着降低(0.38±0.21对3.35±0.77)rhEPO改善了ALT和AST但与I / R组相比,所有组均未能降低FasL表达。用rhEPO(1,000 IU / kg)预处理30分钟和24小时后,Bcl-xL / Bax比值增加,胱天蛋白酶9活性降低,当在缺血前24小时给予更高剂量时,观察到相同的效果。预处理在改善caspase-9活性方面比后处理更有效,并且未观察到剂量依赖性。总之,缺血前30分钟单次IP rhEPO注射比rhEPO后处理在改善肝I / R诱导的细胞凋亡方面具有优势,而没有其他时间和剂量依赖性效应,这可能为肝移植手术提供潜在的指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号